跳至主要内容
临床试验/NCT02310867
NCT02310867招募中2 期

Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

Linda Cendales1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2015年3月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
50
试验地点
1
主要终点
Ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.

研究概览

简要总结

The purpose of this study is to determine the safety and efficacy of hand transplantation as a treatment for patients with loss of limb below the elbow, The study will focus on patients who have had loss of limb. The primary endpoint is the ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.

Study activities include several study visits over 18 months and include; demographics, medical history, vital signs, psychosocial evaluation, urine, blood test, chest x-ray, bone density scans, and biopsies. Subjects who are 18-65 and willing to travel to site and have loss of limb will be included in study evaluation.

Risks of the study include risk of rejection and infection after being transplanted. Additional risk are associated with procedures that include blood draws, biopsies, x-rays, and potential loss of confidentiality. All patient data will be kept electronically and in accordance with the requirements of Duke University. In addition to the experimental data, this database includes recipient and donor demographics and transplant relevant medical history, range of motion, sensation, and immunosuppressive medications. Data will be recorded and reported in accordance with the standards required by the United Network for Organ Sharing (UNOS).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients from 18-65 years old with loss of limb
  • Willingness and legal ability to give informed consent
  • Willingness to travel to study site for protocol specific samples to be taken, or in some cases, the ability to send samples via overnight mail

排除标准

  • Any condition that precludes serial follow-up
  • Any condition that would likely increase the risk of protocol participation or confound the interpretation of the data
  • Any active malignancy or any history of a malignancy or lymphoma
  • Inability or unwillingness to comply with protocol monitoring and therapy and immunodeficiency syndrome(s)

研究组 & 干预措施

Hand transplant with Belatacept

Experimental

干预措施: Belatacept (Drug)

Hand transplant with Belatacept

Experimental

干预措施: Hand transplant (Procedure)

结局指标

主要结局

Ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.

时间窗: 18 months

次要结局

  • Clinical rejection(18 months)
  • Histological rejection(18 months)

研究者

发起方
Linda Cendales
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Linda Cendales

Associate Professor of Surgery

Duke University

研究点 (1)

Loading locations...

相似试验